Hygiena 2011, 56(3):89-94

Prevention and the Economy

Jaroslav Kříž
Choceradská 31, 141 00 Praha 4

The objective of the article is to call attention to economic matters in primary prevention in the Czech Republic and to reveal that primary prevention could save costs in health care in the order of tens of millions euros annually, aside of the contribution to the GDP. A number of methods is available for cost-benefit and cost-effectiveness analyses of preventive interventions. The author presents a consideration on the costs of Disease-Adjusted-Life-Year (DALY) and Quality-Adjusted-Life-Year (QALY) in the Czech Republic and proposes 780.000-1,000.000 CZK/year (32.000-40.000 EUR). In conclusion, the author calls for more discussion on the matters presented and for research of associated problems.

Keywords: primary prevention, economy and prevention, cost-effectiveness, monetary value of DALY and QALY

Received: April 2011; Accepted: August 16, 2011; Published: September 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kříž J. Prevention and the Economy. Hygiena. 2011;56(3):89-94.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bultas J. Farmakoekonomický pohled na léčbu a profylaxi kardiovaskulárních chorob. Remedia. 2006;18(3):2994-7.
    2. Sovinová H, Csémy L, Procházka B, Kottnauerová S. Podíl kuřáctví na hospitalizacích v ČR v roce 2002 a odhad nákladů nemocničního léčení. Hygiena. 2007;52(2):36-42.
    3. Habrová D, Hrubá D. Ekonomika kuřáctví v České republice. Hygiena. 2007;52(4):110-4.
    4. Thorpe KE. Chronic diesease management and prevention in the US: the missing links in health care reform. Eurohealth. 2009;15(1):5-7.
    5. Woolf SH, Husten CG, Lewin LS, Marks JS, Fielding JE, Sanchez EJ. The economic argument for disease prevention: distinguishing between value and savings [Internet]. Washington, DC: Partnership for Prevention; 2009 [cited 2011 Aug 10]. Available from: www.prevent.org/data/files/initiatives/ economicargumentfordiseaseprevention.pdf.
    6. Little AD. Public balance of smoking in the Czech Republic. Report to Philip Morris CR a.s. [Internet]. New York: Tobacco.org; 2000 [cited 2011 Aug 10]. Available from: http://www.tobacco.org/Document/001128pmlittleczech.html.
    7. Pavlatová E. Když uvažuji o zdraví, jsem snící romantik: rozhovor prof. MUDr. J. Holčíka, DrSc. Zdravotnické noviny. 2011;60(4):32-5.
    8. Brent RJ. Cost - benefit analysis and health care evaluation. Celttenham: Edward Elgar Publishing; 2003. Go to original source...
    9. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press; 2005.
    10. Muenning P. Cost - effectiveness analysis in health: a practical approach. 2nd ed. San Francisco: John Willey & Sons; 2007.
    11. Jágrová Z. Efektivita programů primární prevence v okrese Kolín [online]. Praha: IPVZ, Škola veřejného zdravotnictví; 1999 [cit. 2011-08-10]. Dostupný z: www.apra.ipvz/download.asp?docid=104.
    12. Rozenbaum MH, Sanders EA, van Hoek AJ, Jansen AG, van der Ende A, van den Dobbelsteen G, et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ. 2010 Jun 2;340:c2509. Go to original source... Go to PubMed...
    13. Troche CJ, Tacke J, Hinzpeter B, Danner M, Lauterbach KW. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur Heart J. 1998 Apr;19 Suppl C:C59-65. Go to PubMed...
    14. Shepherd J, Kavanagh J, Picot J, Cooper K, Harden A, Barnett-Page E, et al. The effectiveness and cost-effectiveness of behavioural interventions for the prevention of sexually transmitted infections in young people aged 13-19: a systematic review and economic evaluation. Health Technol Assess. 2010 Feb;14(7):1-206. Go to original source... Go to PubMed...
    15. Hutton G. Considerations in evaluating the cost effectiveness of environmental health interventions. WHO/SDE/ WSH/00.10 [Internet]. Geneva: World Health Organization; 2000 [cited 2011 Aug 10]. Available from: http://www.who.int/quantifying_ehimpacts/publications/en/wsh0010exsum.pdf.
    16. Babisch W, editor. Good practice guide on noise exposure and potential health effects. EEA Technical report No. 11/2010. Copenhagen: European Environmental Agency; 2010.
    17. WHO. Quantifying burden of disease form environmental noise: second technical meeting report. Bern, Switzerland 15-16 Dec 2005 [Internet]. Geneva: World Health Organization; 2007 [cited 2011 Aug 10]. Available from: http://www.euro.who.int/__data/assets/pdf_file/0005/87638/Noise_EDB_2nd_mtg.pdf.
    18. Shih YC, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin. 2008 Jul-Aug;58(4):231-44. Go to original source...
    19. Lee CP, Chertow GM, Zenios SA. An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health. 2009 Jan-Feb;12(1):80-7. Go to original source... Go to PubMed...
    20. Towse A. Should NICE's threshold range for cost per QALY be raised? Yes. BMJ. 2009 Jan 26;338:b181. Go to original source... Go to PubMed...
    21. Ščasný M, Urban J. Jaká je cena zdraví? Metodologie oceňování [online]. Praha: Centrum pro otázky životního prostředí UK; 2007 [cit. 2011-08-10]. Dostupný z: http://kvalitazivota.vubp.cz/prispevky/workshop_cena_zdravi/scasny-urban_metodologie.pdf.
    22. Hroboň P. Ekonomické hodnocení preventivních programů: možnosti použití v ČR. Praha: Národohospodářský ústav Josefa Hlávky; 1998.

    Return to the content